It's taken a lot longer than we ever anticipated to get to the...

It's taken a lot longer than we ever anticipated to get to the level we are at today. In that timeframe, the SOI has
increased and the SP has declined, which suggests a long history of unrequited expectations, which in itself is not
'unexpected' in such a speculative pursuit, however, it is worth noting that our first-in-human trial is progressing without
any safety concerns whatsoever and patient recruitment is progressing (albeit at a much slower rate than anticipated)
with every month that passes.

I remain hopeful that more patients have participated in the trial since our last numbers update and with this passage
of time and recruitment experience/trial exposure, we will ultimately satisfy our minimum cohort numbers (10-15) that
are required, as articulated by management.

From the March 2022 Investor Update:
To date, our investigators have completed an evaluation of the first five patients that have completed the study.
Dr. Jane Fox, the study Principal Investigator from Monash Health stated, “We can say that there have been no
safety issues reported related to the MagSense® HER2 imaging agent and that all patients have tolerated the
administration and dosage of the injectable”. Dr Fox added, “we have observed that the imaging agent, as
administered, is capable of reaching the lymph nodes.”

https://imagionbiosystems.com/news/magsense_her2-breast-cancer-first-in-human-study-progress-update/

Time for another update and a change of sentiment.